Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash & Equivalents (2018 - 2025)

Summit Therapeutics' Cash & Equivalents history spans 8 years, with the latest figure at $238.6 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 154.39% year-over-year to $238.6 million; the TTM value through Sep 2025 reached $238.6 million, up 154.39%, while the annual FY2024 figure was $104.9 million, 46.81% up from the prior year.
  • Cash & Equivalents reached $238.6 million in Q3 2025 per SMMT's latest filing, down from $297.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $348.6 million in Q4 2022 to a low of $23.8 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $123.9 million, with a median of $93.8 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: crashed 79.51% in 2023, then soared 947.59% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $103.4 million in 2021, then soared by 237.14% to $348.6 million in 2022, then plummeted by 79.51% to $71.4 million in 2023, then surged by 46.81% to $104.9 million in 2024, then soared by 127.49% to $238.6 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Cash & Equivalents are $238.6 million (Q3 2025), $297.9 million (Q2 2025), and $211.5 million (Q1 2025).